Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study

Basit Öğe Kaydı
dc.authorid0000-0002-2981-8098
dc.authorid0000-0001-9652-7058
dc.authorid0000-0002-7401-5446
dc.authorid0000-0002-7917-2459
dc.authorid0000-0002-0853-4096
dc.authorid0000-0003-1466-3887
dc.authorid0000-0003-3060-377X
dc.contributor.authorYildirim, Hasan Cagri
dc.contributor.authorKapar, Caner
dc.contributor.authorKoksal, Baris
dc.contributor.authorSeyyar, Mustafa
dc.contributor.authorSanci, Pervin Can
dc.contributor.authorGuliyev, Murad
dc.contributor.authorPerkin, Perihan
dc.date.accessioned2026-01-24T12:31:27Z
dc.date.available2026-01-24T12:31:27Z
dc.date.issued2025
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractThe only phase 3 study on the effectiveness of CDK 4-6 inhibitors in first-line treatment in premenopausal patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer is the MONALEESA-7 study, and data on the effectiveness of palbociclib is limited. Data are also limited regarding the effectiveness of CDK 4-6 inhibitors in patients whose dose was reduced due to neutropenia, the most common side effect of CDK 4-6 inhibitors. In our study, we aimed to evaluate the effectiveness of palbociclib and ribociclib in first-line treatment in patients with premenopausal metastatic breast cancer and the effect of dose reduction due to neutropenia on progression-free survival. Our study is a multicenter, retrospective study, and factors affecting progression-free survival (PFS) were examined in patients diagnosed with metastatic premenopausal breast cancer from 29 different centers and receiving combination therapy containing palbociclib or ribociclib in the metastatic stage. 319 patients were included in the study. The mPFS for patients treated with palbociclib was 26.83 months, and for those receiving ribociclib, the mPFS was 29.86 months (p = 0.924). mPFS was 32.00 months in patients who received a reduced dose, and mPFS was 25.96 months in patients who could take the initial dose, and there was no statistical difference (p = 0.238). Liver metastasis, using a fulvestrant together with a CDK 4-6 inhibitor, ECOG PS 1 was found to be a negative prognostic factor. No new adverse events were observed. In our study, we found PFS over 27 months in patients diagnosed with premenopausal breast cancer with CDK 4-6 inhibitors used in first-line treatment, similar to post-menopausal patients. We did not detect any difference between the effectiveness of the two CDK 4-6 inhibitors, and we showed that there was no decrease in the effectiveness of the CDK 4-6 inhibitor in patients whose dose was reduced due to neutropenia.
dc.identifier.doi10.1080/1120009X.2024.2330835
dc.identifier.endpage75
dc.identifier.issn1120-009X
dc.identifier.issn1973-9478
dc.identifier.issue1
dc.identifier.pmid38497444
dc.identifier.startpage69
dc.identifier.urihttps://doi.org/10.1080/1120009X.2024.2330835
dc.identifier.urihttps://hdl.handle.net/20.500.12868/5894
dc.identifier.volume37
dc.identifier.wosWOS:001187079800001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofJournal of Chemotherapy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260121
dc.subjectPremenopausal breast cancer
dc.subjectlow-dose treatment
dc.titleEfficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu